Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SGLT6 - A pharmacological target for the treatment of obesity?
Baader-Pagler T, Eckhardt M, Himmelsbach F, Sauer A, Stierstorfer BE, Hamilton BS. Baader-Pagler T, et al. Among authors: himmelsbach f. Adipocyte. 2018;7(4):277-284. doi: 10.1080/21623945.2018.1516098. Epub 2018 Oct 11. Adipocyte. 2018. PMID: 30161013 Free PMC article.
Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational study.
Kozik-Jaromin J, Röseler E, Heigl F, Spitthöver R, Ringel J, Schmitz G, Heinzler R, Abdul-Rahman N, Leistikow F, Himmelsbach F, Schettler V, Uhlenbusch-Körwer I, Ramlow W. Kozik-Jaromin J, et al. Among authors: himmelsbach f. Atheroscler Suppl. 2017 Nov;30:225-231. doi: 10.1016/j.atherosclerosissup.2017.05.036. Atheroscler Suppl. 2017. PMID: 29096842
Efficacy of lipid reduction with DALI and MONET.
Ramlow W, Röseler E, Heigl F, Spitthöver R, Ringel J, Schmitz G, Heinzler R, Abdul-Rahman N, Leistikow F, Himmelsbach F, Schettler V, Pham J, Kozik-Jaromin J. Ramlow W, et al. Among authors: himmelsbach f. Atheroscler Suppl. 2017 Nov;30:217-224. doi: 10.1016/j.atherosclerosissup.2017.05.035. Epub 2017 Jun 1. Atheroscler Suppl. 2017. PMID: 29096841
Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.
Zhuang L, Tice CM, Xu Z, Zhao W, Cacatian S, Ye YJ, Singh SB, Lindblom P, McKeever BM, Krosky PM, Zhao Y, Lala D, Kruk BA, Meng S, Howard L, Johnson JA, Bukhtiyarov Y, Panemangalore R, Guo J, Guo R, Himmelsbach F, Hamilton B, Schuler-Metz A, Schauerte H, Gregg R, McGeehan GM, Leftheris K, Claremon DA. Zhuang L, et al. Among authors: himmelsbach f. Bioorg Med Chem. 2017 Jul 15;25(14):3649-3657. doi: 10.1016/j.bmc.2017.04.033. Epub 2017 Apr 29. Bioorg Med Chem. 2017. PMID: 28528082
Sequential C-H Arylation and Enantioselective Hydrogenation Enables Ideal Asymmetric Entry to the Indenopiperidine Core of an 11β-HSD-1 Inhibitor.
Wei X, Qu B, Zeng X, Savoie J, Fandrick KR, Desrosiers JN, Tcyrulnikov S, Marsini MA, Buono FG, Li Z, Yang BS, Tang W, Haddad N, Gutierrez O, Wang J, Lee H, Ma S, Campbell S, Lorenz JC, Eckhardt M, Himmelsbach F, Peters S, Patel ND, Tan Z, Yee NK, Song JJ, Roschangar F, Kozlowski MC, Senanayake CH. Wei X, et al. Among authors: himmelsbach f. J Am Chem Soc. 2016 Nov 30;138(47):15473-15481. doi: 10.1021/jacs.6b09764. Epub 2016 Nov 17. J Am Chem Soc. 2016. PMID: 27794616 Free PMC article.
Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.
Hamilton BS, Himmelsbach F, Nar H, Schuler-Metz A, Krosky P, Guo J, Guo R, Meng S, Zhao Y, Lala DS, Zhuang L, Claremon DA, McGeehan GM. Hamilton BS, et al. Among authors: himmelsbach f. Eur J Pharmacol. 2015 Jan 5;746:50-5. doi: 10.1016/j.ejphar.2014.10.053. Epub 2014 Nov 8. Eur J Pharmacol. 2015. PMID: 25445047
26 results